Ekso Bionics (NASDAQ:EKSO) Stock Rating Upgraded by ValuEngine

Ekso Bionics (NASDAQ:EKSO) was upgraded by equities researchers at ValuEngine from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday, ValuEngine reports.

Several other analysts have also commented on EKSO. HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Ekso Bionics in a report on Friday, July 31st. Zacks Investment Research lowered Ekso Bionics from a “buy” rating to a “hold” rating in a report on Thursday, August 20th. Finally, Aegis decreased their price objective on Ekso Bionics from $13.00 to $9.00 and set a “buy” rating for the company in a report on Monday, August 3rd. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $8.81.

Ekso Bionics stock opened at $5.44 on Tuesday. The business has a fifty day moving average of $5.56 and a two-hundred day moving average of $4.27. The company has a quick ratio of 2.46, a current ratio of 2.79 and a debt-to-equity ratio of 0.11. The firm has a market cap of $44.99 million, a P/E ratio of -1.86 and a beta of 2.09. Ekso Bionics has a twelve month low of $2.25 and a twelve month high of $11.78.

Ekso Bionics (NASDAQ:EKSO) last posted its earnings results on Thursday, July 30th. The company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($1.32). The company had revenue of $2.26 million for the quarter, compared to analysts’ expectations of $1.85 million. Ekso Bionics had a negative return on equity of 275.25% and a negative net margin of 156.16%. Equities analysts expect that Ekso Bionics will post -0.65 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of EKSO. Atom Investors LP purchased a new position in Ekso Bionics in the 2nd quarter worth $630,000. Bank of Montreal Can raised its stake in Ekso Bionics by 2,233.5% in the 2nd quarter. Bank of Montreal Can now owns 18,808 shares of the company’s stock worth $138,000 after acquiring an additional 18,002 shares during the last quarter. Strategic Wealth Designers purchased a new position in Ekso Bionics in the 2nd quarter worth $114,000. Finally, WINTON GROUP Ltd raised its stake in Ekso Bionics by 45.9% in the 2nd quarter. WINTON GROUP Ltd now owns 19,887 shares of the company’s stock worth $167,000 after acquiring an additional 6,256 shares during the last quarter. Institutional investors own 13.64% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.

Recommended Story: Forex

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.